OST-499
Uterine fibroids, Colon cancer
Phase IActive
Key Facts
About Oncostellae
Oncostellae is a Spanish biotechnology startup developing innovative, small-molecule therapeutics for oncology and inflammatory/autoimmune diseases. Its strategy centers on creating novel chemical scaffolds targeting clinically validated pathways, with a lead program, OST-122, demonstrating promising Phase 2a proof-of-concept in ulcerative colitis. The company operates a capital-efficient model, advancing programs to clinical proof-of-concept before out-licensing to pharmaceutical partners for late-stage development and commercialization.
View full company profile